$ARWR

Arrowhead Pharmaceuticals (NASDAQ: ARWR) said the European Commission approved REDEMPLO (plozasiran) in June 2026, and it is now listed in Germany’s Lauer-Taxe database for prescribing and reimbursement. REDEMPLO is used with diet for adult FCS patients, with dosing as a subcutaneous injection every three months. Phase 3 PALISADE showed significant fasting triglyceride reductions at Month 10 versus placebo; common adverse reactions included hyperglycaemia and headache.

Arrowhead Pharmaceuticals (ARWR) disclosed that Avoro Capital Advisors LLC and controlling person Behzad Aghazadeh beneficially own 13,823,383 shares, including 2,467,828 shares issuable on warrant exercise. Using 140,857,021 shares outstanding as of May 1, 2026, the stake equals 9.64% assuming warrants are exercised.

Simply Wall St highlights Arrowhead Pharmaceuticals (ARWR) after its Q3 2026 results, citing sales of $75.25M and a net loss of $194.28M. The stock trades at $89.24, up 16.81% over 30 days and 31.64% YTD. The article compares fair value estimates around $89.08 and a DCF cash-flow value of $174.62, noting risks from milestones and clinical or regulatory setbacks.

Arrowhead Pharmaceuticals (ARWR) reported Q3 2026 results. Sales rose to $75.25 million from $27.77 million a year earlier, but net loss widened to $194.28 million and loss per share increased to $1.36 from $1.26. For the first nine months of 2026, it swung to a $296.21 million net loss despite $400+ million in sales, citing higher expenses and lower collaboration revenue.

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 arwr-202608048kex991.htm EX-99.1 Document EXHIBIT 99.1 PRESS RELEASE August 4, 2026 Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results Conference Call and Webcast Today, August 4, 2026 at 4:30 p.m. ET PASADENA, Calif., August 4, 2026 — Arrowhead Pharmac

Arrowhead Pharmaceuticals (ARWR) said its Phase 3 SHASTA-3 and SHASTA-4 trials of plozasiran in severe hypertriglyceridemia met primary and secondary endpoints, and it completed enrollment for the Phase 3 YOSEMITE trial of zodasiran in homozygous familial hypercholesterolemia. The article cites projected 2029 revenue of $704.7M and earnings of $133.3M.

RBC raised its price target on Arrowhead Pharmaceuticals to $100 from $87 and kept an Outperform rating, according to the bank. The article describes Arrowhead’s RNA interference drug platform and notes it has multiple clinical-stage candidates, including plozasiran and zodasiran.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) said it completed enrollment in the global Phase 3 YOSEMITE trial of zodasiran for homozygous familial hypercholesterolemia. The study enrolled 70 patients (2:1 randomization) and is expected to complete in mid-2027. The primary endpoint is percent change in fasting LDL-C at month 12.

Arrowhead Pharmaceuticals (ARWR) reported phase 3 trial results in severe hypertriglyceridemia, aiming for an FDA submission and potential approval in the same indication. Ionis (IONS) recently expanded FDA labeling for Tryngolza, the first therapy approved for severe hypertriglyceridemia. The data could set up direct competition between ARWR and IONS.

Trefis says Arrowhead Pharmaceuticals (ARWR) has shifted from R&D to commercialization after its first approved drug, REDEMPLO, began selling, with over 400 prescriptions written. It reports Phase 3 SHASTA-3 and SHASTA-4 met primary endpoints. The article cites about $10.6B market cap, P/S 17.1, operating margin -36%, and nearly $1.8B cash.